Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

HIV generic drug for babies distributed in Africa, says UNITAID

The strawberry-flavoured tablet is the first generic child version of a key anti-retroviral

Reuters Staff
Monday 05 July 2021 15:56 BST
Comments
Some 1.8 million children worldwide live with HIV yet only half recieve any treatment for it
Some 1.8 million children worldwide live with HIV yet only half recieve any treatment for it (Getty Images)
Leer en Español

Your support helps us to tell the story

This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.

The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.

Help us keep bring these critical stories to light. Your support makes all the difference.

Aid agencies have distributed a strawberry-flavoured tablet for children living with HIV in six African countries, the first generic pediatric version of a key anti-retroviral, global health agency UNITAID said.

UNITAID and Clinton Health Access Initiative (CHAI) funding procured 100,000 packs of the dolutegravir formulation across Nigeria, Malawi, Uganda, Kenya, Zimbabwe and Benin, UNITAD’s spokesman Herve Verhoosel said in statement to Reuters.

Some 1.8 million children worldwide live with HIV, but only half receive any treatment, often hard to administer due to the bitter taste or incorrectly dosed by crushing adult pills. Some 100,000 children die of AIDS annually.

“With the recent delivery of the formulation in those six first countries, this project is now reality,” Verhoosel, who is visiting the United Arab Emirates, said of the initiative first announced last December.

He said this procurement is designed to kickstart demand and that major donors have “rapidly moved to sustainable onward procurement, which will enable national scale-up and widespread access for all eligible children at an unprecedented pace”.

The first-line HIV treatment is recommended by the World Health Organisation from the age of four weeks and 3 kilos (6.6 pounds), but it had been out of reach for babies because of the lack of appropriate formulations.

UNITAID and CHAI had reached a pricing agreement with the generic drugmakers Viatris and Macleods for the dispersible pediatric formulation of dolutegravir.

The estimated cost for combination therapy will now be some $120 (£87) for a child’s annual treatment, against $480 (£347) currently, making it a “game-changer” for poorer countries, UNITAID said.

Verhoosel said a partnership with Medicines Patent Pool allowed for voluntary licensing agreements across 121 countries.

Reuters

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in